Nautilus Biotechnology installed its single‑molecule protein analysis system at the Buck Institute for Research on Aging as the first external customer deployment, enabling targeted studies of tau proteoforms in neurodegeneration. The Buck team plans to use Nautilus’s DNA‑origami‑based chips and iterative probing workflow to dissect tau isoforms and post‑translational modifications at single‑molecule scale. Nautilus reported performance metrics in a bioRxiv preprint and said the Buck installation is a step toward an early‑access program for targeted applications in the first half of 2026. The company’s stock jumped about 39% on the news, reflecting investor enthusiasm for single‑molecule proteomics as a new layer beyond genomics. Early access will focus on targeted proteoform analyses such as tau, with longer‑term aims to scale toward broader proteome studies pending reagent and informatics development.